Ruichu Cai1, Mei Liu2, Yong Hu3, Brittany L Melton4, Michael E Matheny5, Hua Xu6, Lian Duan7, Lemuel R Waitman8. 1. Faculty of Computer Science, Guangdong University of Technology, Guangzhou, People's Republic of China. Electronic address: cairuichu@gmail.com. 2. Department of Internal Medicine, Division of Medical Informatics, University of Kansas Medical Center, Kansas City, 66160, USA. Electronic address: meiliu@kumc.edu. 3. Big Data Decision Institute, Jinan University, Guangzhou, People's Republic of China. 4. School of Pharmacy, University of Kansas, Lawrence, USA. 5. Geriatric Research Education & Clinical Care, Tennessee Valley Healthcare System, Veteran's Health Administration, Nashville, USA; Department of Biomedical Informatics, Department of Medicine, Division of General Internal Medicine, & Department of Biostatistics, Vanderbilt University, Nashville, USA. 6. School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, USA. 7. Departent of Information Systems and Business Analytics, Hofstra University, Hempstead, USA. 8. Department of Internal Medicine, Division of Medical Informatics, University of Kansas Medical Center, Kansas City, 66160, USA.
Abstract
OBJECTIVE: Drug-drug interaction (DDI) is of serious concern, causing over 30% of all adverse drug reactions and resulting in significant morbidity and mortality. Early discovery of adverse DDI is critical to prevent patient harm. Spontaneous reporting systems have been a major resource for drug safety surveillance that routinely collects adverse event reports from patients and healthcare professionals. In this study, we present a novel approach to discover DDIs from the Food and Drug Administration's adverse event reporting system. METHODS: Data-driven discovery of DDI is an extremely challenging task because higher-order associations require analysis of all combinations of drugs and adverse events and accurate estimate of the relationships between drug combinations and adverse event require cause-and-effect inference. To efficiently identify causal relationships, we introduce the causal concept into association rule mining by developing a method called Causal Association Rule Discovery (CARD). The properties of V-structures in Bayesian Networks are utilized in the search for causal associations. To demonstrate feasibility, CARD is compared to the traditional association rule mining (AR) method in DDI identification. RESULTS: Based on physician evaluation of 100 randomly selected higher-order associations generated by CARD and AR, CARD is demonstrated to be more accurate in identifying known drug interactions compared to AR, 20% vs. 10% respectively. Moreover, CARD yielded a lower number of drug combinations that are unknown to interact, i.e., 50% for CARD and 79% for AR. CONCLUSION: Evaluation analysis demonstrated that CARD is more likely to identify true causal drug variables and associations to adverse event.
OBJECTIVE: Drug-drug interaction (DDI) is of serious concern, causing over 30% of all adverse drug reactions and resulting in significant morbidity and mortality. Early discovery of adverse DDI is critical to prevent patient harm. Spontaneous reporting systems have been a major resource for drug safety surveillance that routinely collects adverse event reports from patients and healthcare professionals. In this study, we present a novel approach to discover DDIs from the Food and Drug Administration's adverse event reporting system. METHODS: Data-driven discovery of DDI is an extremely challenging task because higher-order associations require analysis of all combinations of drugs and adverse events and accurate estimate of the relationships between drug combinations and adverse event require cause-and-effect inference. To efficiently identify causal relationships, we introduce the causal concept into association rule mining by developing a method called Causal Association Rule Discovery (CARD). The properties of V-structures in Bayesian Networks are utilized in the search for causal associations. To demonstrate feasibility, CARD is compared to the traditional association rule mining (AR) method in DDI identification. RESULTS: Based on physician evaluation of 100 randomly selected higher-order associations generated by CARD and AR, CARD is demonstrated to be more accurate in identifying known drug interactions compared to AR, 20% vs. 10% respectively. Moreover, CARD yielded a lower number of drug combinations that are unknown to interact, i.e., 50% for CARD and 79% for AR. CONCLUSION: Evaluation analysis demonstrated that CARD is more likely to identify true causal drug variables and associations to adverse event.
Authors: Hae Reong Kim; MinDong Sung; Ji Ae Park; Kyeongseob Jeong; Ho Heon Kim; Suehyun Lee; Yu Rang Park Journal: Medicine (Baltimore) Date: 2022-06-24 Impact factor: 1.817
Authors: Danai Chasioti; Xiaohui Yao; Pengyue Zhang; Samuel Lerner; Sara K Quinney; Xia Ning; Lang Li; Li Shen Journal: IEEE J Biomed Health Inform Date: 2018-10-08 Impact factor: 5.772
Authors: Ehtesham Iqbal; Robbie Mallah; Daniel Rhodes; Honghan Wu; Alvin Romero; Nynn Chang; Olubanke Dzahini; Chandra Pandey; Matthew Broadbent; Robert Stewart; Richard J B Dobson; Zina M Ibrahim Journal: PLoS One Date: 2017-11-09 Impact factor: 3.240